I agree. pretty surprised by the ADLR deal and seems like a steep price to pay for Entereg plus an OIC candidate that is quite a bit behind others in the space. Will be interested to hear the conference call on this one.
Any comments here may have previously been disseminated on Twitter @BioDueDiligence or at www.biotechduediligence.com